First-in-human (phase I) trial of SOL-116, a humanised IgG4 monoclonal antibody targeting bile salt-stimulated lipase, in healthy participants and rheumatoid arthritis patients

Objective Bile salt-stimulated lipase (BSSL) is a digestive lipolytic enzyme and a potential novel drug target for treatment of rheumatoid arthritis (RA). Here, we report the results of the first-in-human study of SOL-116, a first-in-class humanised IgG4 monoclonal antibody targeting BSSL, conducted...

詳細記述

書誌詳細

主要な著者:	Olle Hernell, Naomi B Klarenbeek, Susanne Lindquist, Anouk C Meijs, Johan Kolmert, Peter Hovstadius, Hendrika W Grievink, Anneli Hällgren, Agneta Wennerholm
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMJ Publishing Group 2026-06-01
シリーズ:	RMD Open
オンライン･アクセス:	https://rmdopen.bmj.com/content/12/2/e006712.full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!